Your browser doesn't support javascript.
Predicting SARS-CoV-2 Variant Spread in a Completely Seropositive Population Using Semi-Quantitative Antibody Measurements in Blood Donors.
Buss, Lewis; Prete, Carlos A; Whittaker, Charles; Salomon, Tassila; Oikawa, Marcio K; Pereira, Rafael H M; Moura, Isabel C G; Delerino, Lucas; Franca, Rafael F O; Miyajima, Fabio; Mendrone, Alfredo; Almeida-Neto, Cesar; Salles, Nanci A; Ferreira, Suzete C; Fladzinski, Karine A; de Souza, Luana M; Schier, Luciane K; Inoue, Patricia M; Xabregas, Lilyane A; Crispim, Myuki A E; Fraiji, Nelson; Carlos, Luciana M B; Pessoa, Veridiana; Ribeiro, Maisa A; de Souza, Rosenvaldo E; Cavalcante, Anna F; Valença, Maria I B; da Silva, Maria V; Lopes, Esther; Filho, Luiz A; Mateos, Sheila O G; Nunes, Gabrielle T; Schlesinger, David; da Silva, Sônia Mara Nunes; Silva-Junior, Alexander L; Castro, Marcia C; Nascimento, Vítor H; Dye, Christopher; Busch, Michael P; Faria, Nuno R; Sabino, Ester C.
  • Buss L; MRC Centre for Global Infectious Disease Analysis, Imperial College London, London SW7 2BX, UK.
  • Prete CA; Department of Electronic Systems Engineering, University of São Paulo, São Paulo 05508-010, Brazil.
  • Whittaker C; MRC Centre for Global Infectious Disease Analysis, Imperial College London, London SW7 2BX, UK.
  • Salomon T; Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte 30130-110, Brazil.
  • Oikawa MK; Center of Mathematics, Computing and Cognition, Universidade Federal do ABC, Santo André 09210-170, Brazil.
  • Pereira RHM; Institute for Applied Economic Research (Ipea), Brasília 70390-025, Brazil.
  • Moura ICG; Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte 30130-110, Brazil.
  • Delerino L; Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, Brazil.
  • Franca RFO; Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, Brazil.
  • Miyajima F; Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, Brazil.
  • Mendrone A; Universidade Federal do Ceará, Fortaleza 60455-760, Brazil.
  • Almeida-Neto C; Fundação Pró Sangue Hemocentro de São Paulo (FPS), Sao Paulo 05403-000, Brazil.
  • Salles NA; Fundação Pró Sangue Hemocentro de São Paulo (FPS), Sao Paulo 05403-000, Brazil.
  • Ferreira SC; Fundação Pró Sangue Hemocentro de São Paulo (FPS), Sao Paulo 05403-000, Brazil.
  • Fladzinski KA; Fundação Pró Sangue Hemocentro de São Paulo (FPS), Sao Paulo 05403-000, Brazil.
  • de Souza LM; Centro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba 80045-145, Brazil.
  • Schier LK; Centro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba 80045-145, Brazil.
  • Inoue PM; Centro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba 80045-145, Brazil.
  • Xabregas LA; Centro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba 80045-145, Brazil.
  • Crispim MAE; Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus 69050-001, Brazil.
  • Fraiji N; Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus 69050-001, Brazil.
  • Carlos LMB; Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus 69050-001, Brazil.
  • Pessoa V; Centro de Hematologia e Hemoterapia do Ceará (HEMOCE), Fortaleza 60140-200, Brazil.
  • Ribeiro MA; Centro de Hematologia e Hemoterapia do Ceará (HEMOCE), Fortaleza 60140-200, Brazil.
  • de Souza RE; Fundação Hemominas, Belo Horizonte 30150-341, Brazil.
  • Cavalcante AF; Fundação Hemominas, Belo Horizonte 30150-341, Brazil.
  • Valença MIB; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife 52011-000, Brazil.
  • da Silva MV; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife 52011-000, Brazil.
  • Lopes E; Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE), Recife 52011-000, Brazil.
  • Filho LA; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro 20211-030, Brazil.
  • Mateos SOG; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro 20211-030, Brazil.
  • Nunes GT; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro 20211-030, Brazil.
  • Schlesinger D; Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro 20211-030, Brazil.
  • da Silva SMN; Mendelics, São Paulo 02511-000, Brazil.
  • Silva-Junior AL; Fundação Hemominas, Belo Horizonte 30150-341, Brazil.
  • Castro MC; Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus 69050-001, Brazil.
  • Nascimento VH; Universidade Federal do Amazonas, Manaus 69067-005, Brazil.
  • Dye C; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Busch MP; Department of Electronic Systems Engineering, University of São Paulo, São Paulo 05508-010, Brazil.
  • Faria NR; Department of Zoology, University of Oxford, Oxford OX1 3SZ, UK.
  • Sabino EC; Vitalant Research Institute, Denver, CO 80230, USA.
Vaccines (Basel) ; 10(9)2022 Aug 31.
Article in English | MEDLINE | ID: covidwho-2006269
ABSTRACT
SARS-CoV-2 serologic surveys estimate the proportion of the population with antibodies against historical variants, which nears 100% in many settings. New approaches are required to fully exploit serosurvey data. Using a SARS-CoV-2 anti-Spike (S) protein chemiluminescent microparticle assay, we attained a semi-quantitative measurement of population IgG titers in serial cross-sectional monthly samples of blood donations across seven Brazilian state capitals (March 2021-November 2021). Using an ecological analysis, we assessed the contributions of prior attack rate and vaccination to antibody titer. We compared anti-S titer across the seven cities during the growth phase of the Delta variant and used this to predict the resulting age-standardized incidence of severe COVID-19 cases. We tested ~780 samples per month, per location. Seroprevalence rose to >95% across all seven capitals by November 2021. Driven by vaccination, mean antibody titer increased 16-fold over the study, with the greatest increases occurring in cities with the highest prior attack rates. Mean anti-S IgG was strongly correlated (adjusted R2 = 0.89) with the number of severe cases caused by Delta. Semi-quantitative anti-S antibody titers are informative about prior exposure and vaccination coverage and may also indicate the potential impact of future SARS-CoV-2 variants.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10091437

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10091437